Obesity
Eli Lilly to Seek FDA Approval of Retatrutide, Its Most Powerful Obesity Drug Yet
New Triumph trial data show 21–23% weight loss in patients with diabetes or heart disease, setting up a 2027 filing for Lilly's triple-hormone drug.